Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Immunology

Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein

Leukemia volume 20, pages 2025–2033 (2006)Cite this article

Abstract

Wilms tumor protein 1 (WT1) is a transcription factor overexpressed in several types of leukemia and solid tumors. For this reason, WT1 is an attractive target for immunotherapy. Four peptide nonamers from WT1 have been identified by others to generate a WT1-specific cytotoxic response in the context of human leukocyte antigen (HLA)-A0201 and A2402. However, as WT1 is a self-antigen, breaking tolerance is a potential obstacle to vaccination. Here, we use a strategy to circumvent tolerance by designing synthetic immunogenic analog peptides that could crossreact to the native peptides (a heteroclitic response). A number of synthetic peptides derived from nonamer sequences of the WT1 protein were designed in which single amino-acid substitutions were introduced at HLA-A0201 major histocompatibility complex (MHC)-binding positions. Several of new peptides could stabilize MHC class I A0201 molecules better than native sequences. Some analogs were also able to elicit WT1-specific T-cell recognition and cytotoxic T-cell lymphocytes more effectively than native sequences. Importantly, T cells stimulated with the new analogs crossreacted with the native WT1 peptide sequence and were able to kill HLA-matched chronic myeloid leukemia cell lines. In conclusion, analog heteroclitic WT1 peptides with increased immunogenicity can be synthesized and are potential cancer vaccine candidates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509–520.

    Article  CAS  PubMed  Google Scholar 

  2. Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990; 346: 194–197.

    Article  CAS  PubMed  Google Scholar 

  3. Huang A, Campbell CE, Bonetta L, McAndrews-Hill MS, Chilton-MacNeill S, Coppes MJ et al. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor. Science 1990; 250: 991–994.

    Article  CAS  PubMed  Google Scholar 

  4. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L . The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997; 25: 945–950.

    CAS  PubMed  Google Scholar 

  5. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D et al. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993; 4: 415–420.

    Article  CAS  PubMed  Google Scholar 

  6. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D . Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev 1991; 5: 1345–1356.

    Article  CAS  PubMed  Google Scholar 

  7. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405–1412.

    CAS  PubMed  Google Scholar 

  8. Brieger J, Weidmann E, Maurer U, Hoelzer D, Mitrou PS, Bergmann L . The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann Oncol 1995; 6: 811–816.

    Article  CAS  PubMed  Google Scholar 

  9. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003; 21: 1988–1995.

    Article  CAS  PubMed  Google Scholar 

  10. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969–2976.

    CAS  PubMed  Google Scholar 

  12. Svedberg H, Chylicki K, Baldetorp B, Rauscher III FJ, Gullberg U . Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. Oncogene 1998; 16: 925–932.

    Article  CAS  PubMed  Google Scholar 

  13. Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 2001; 7 (3 Suppl): 761s–765s.

    CAS  PubMed  Google Scholar 

  14. Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272–3279.

    Article  CAS  PubMed  Google Scholar 

  15. Knights AJ, Zaniou A, Rees RC, Pawelec G, Muller L . Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124–138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 2002; 51: 271–281.

    Article  CAS  PubMed  Google Scholar 

  16. Muller L, Knights A, Pawelec G . Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. Hematol J 2003; 4: 57–66.

    Article  PubMed  Google Scholar 

  17. Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood 2005; 106: 1415–1418.

    Article  CAS  PubMed  Google Scholar 

  18. Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006; 55: 850–860.

    Article  CAS  PubMed  Google Scholar 

  19. Ohminami H, Yasukawa M, Fujita S . HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286–293.

    CAS  PubMed  Google Scholar 

  20. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51: 99–107.

    Article  CAS  PubMed  Google Scholar 

  21. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198–2203.

    CAS  PubMed  Google Scholar 

  22. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51: 614–620.

    Article  CAS  PubMed  Google Scholar 

  23. Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002; 100: 3835–3837.

    Article  CAS  PubMed  Google Scholar 

  24. Doubrovina ES, Doubrovin MM, Lee S, Shieh JH, Heller G, Pamer E et al. In vitro stimulation with WT1 peptide-loaded Epstein–Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Clin Cancer Res 2004; 10: 7207–7219.

    Article  CAS  PubMed  Google Scholar 

  25. Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004; 53: 617–624.

    Article  CAS  PubMed  Google Scholar 

  26. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000; 20: 195–202.

    Article  CAS  PubMed  Google Scholar 

  27. Gao L, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 2003; 75: 1429–1436.

    Article  PubMed  Google Scholar 

  28. Gomez-Nunez M, Pinilla-Ibarz J, Dao T, May RJ, Pao M, Jaggi JS et al. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res 2006; March 11 [Epub ahead of print].

  29. Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde KH, Wolfel T . The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 1997; 203: 141–152.

    Article  CAS  PubMed  Google Scholar 

  30. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.

    Article  CAS  PubMed  Google Scholar 

  31. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A . Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74: 929–937.

    Article  CAS  PubMed  Google Scholar 

  32. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000; 30: 3411–3421.

    Article  CAS  PubMed  Google Scholar 

  33. Sugiyama H . Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001; 73: 177–187.

    Article  CAS  PubMed  Google Scholar 

  34. Sugiyama H . Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol Med 2002; 68: 223–237.

    CAS  PubMed  Google Scholar 

  35. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23: 499–505.

    Article  CAS  PubMed  Google Scholar 

  36. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878–2884.

    CAS  PubMed  Google Scholar 

  37. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132–2137.

    Article  CAS  PubMed  Google Scholar 

  38. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892–2900.

    Article  CAS  PubMed  Google Scholar 

  39. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005; 11 (24 Part 1): 8799–8807.

    Article  CAS  PubMed  Google Scholar 

  40. Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S et al. Ex vivo characterization of multiepitopic tumor-specific CD8T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005; 174: 8210–8218.

    Article  CAS  PubMed  Google Scholar 

  41. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U . Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165–166.

    Article  CAS  PubMed  Google Scholar 

  43. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153: 5586–5592.

    CAS  PubMed  Google Scholar 

  44. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ . Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996; 156: 3308–3314.

    CAS  PubMed  Google Scholar 

  45. Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K et al. Changes in the fine specificity of gp100(209–217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 1999; 162: 1749–1755.

    CAS  PubMed  Google Scholar 

  46. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996; 157: 2539–2548.

    CAS  PubMed  Google Scholar 

  47. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. Nat Med 1998; 4: 321–327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Valmori D, Fonteneau JF, Valitutti S, Gervois N, Dunbar R, Lienard D et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol 1999; 11: 1971–1980.

    Article  CAS  PubMed  Google Scholar 

  49. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005; 106: 3062–3067.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Hans Stauss for providing some of the cell lines used in this paper. This work was supported by NIH PO1 23766, RO1 55349, F32-CA119479A, The Doris Duke Charitable Foundation, The Lymphoma Foundation, The William and Alice Goodwin Commonwealth Foundation for Cancer Research. JPI was an ASCO Young Investigator 03-04 and DAS is a Doris Duke Distinguished Clinical Scientist.

Author information

Authors and Affiliations

  1. Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    J Pinilla-Ibarz, R J May, T Korontsvit, M Gomez, B Kappel, V Zakhaleva, R H Zhang & D A Scheinberg

Authors
  1. J Pinilla-Ibarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R J May
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Korontsvit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Gomez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Kappel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V Zakhaleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R H Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D A Scheinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to J Pinilla-Ibarz or D A Scheinberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pinilla-Ibarz, J., May, R., Korontsvit, T. et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 20, 2025–2033 (2006). https://doi.org/10.1038/sj.leu.2404380

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404380

Keywords

This article is cited by

Search

Advanced search

Quick links